KSKirsty Stuart

Kirsty Stuart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kirsty Stuart has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of four breast lymphoedema patient reported outcome measures in women following breast conserving surgery and radiotherapy: examination of frequencies of symptoms and measurement properties

    by Nicola Fearn, Sharon Kilbreath, Elizabeth Dylke, Wei Wang, Catalina Llanos, Verity Ahern, Elisabeth Elder, Farid Meybodi, Nicholas Olsen, Kirsty Stuart

    Background: Lymphoedema of the breast is a potential consequence of breast cancer treatment. Questionnaires exist to quantify breast symptoms but evidence for measurement properties is limited. This study aimed to evaluate measurement properties of breast lymphoedema questionnaires and report on frequency and severity of breast symptoms in women with breast cancer. Methods: Women following breast conserving surgery and radiotherapy were recruited. Four questionnaires, Breast Lymphoedema Severity Symptom questionnaire (BLYSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Symptom Subscale (EORTC-QLQ-BSS), Lymphoedema Symptom Intensity and Distress scale–Trunk (LSIDS-T) and Breast Oedema Bother scale (BOB), were completed three and nine-months after radiotherapy. Measurement properties and breast symptoms were evaluated. Results: Questionnaires were completed by 164 women at three-months, and 152 at nine-months post radiotherapy. Internal consistency was strong for all questionnaires (McDonald’s Omega and Cronbach’s ⍺ ≥0.7). Correlation between BLYSS and EORTC-QLQ-BSS and BOB visual analogue scale (BOB-VAS) met the hypothesised level (r s ≥ 0.7) demonstrating construct validity. Exploratory factor analysis demonstrated single factors for individual tools and four factors when all four questionnaires were combined: pain, swelling, breast sensations and hardness. Responsiveness was high for BLYSS and moderate for EORTC-QLQ-BSS and BOB-VAS. Over half the women experienced symptoms ≥twice/week at mild-extreme severity. Breast pain, hardness, oversensitivity and swelling were most reported symptoms. Conclusion: The BLYSS demonstrated the strongest measurement properties among the PROMs evaluated with strong internal consistency, construct validity and responsiveness. Breast symptoms were commonly experienced by women after breast cancer treatment.

  • Open Access

    Standardization of breast radiotherapy structure nomenclature using transformer-based multi-modal feature learning

    by Fahim Irfan Alam, Matthew Field, Daniel Al Mouiee, Phillip Chlap, Geoff P. Delaney, Shalini K. Vinod, Shivani Kumar, Janet Cui, Ali Haidar, Vicky Chin, et al.

  • Open Access

    Breast sensation following nipple-sparing mastectomy versus breast-conserving surgery: a mixed-methods study

    by Josette Mouawad, James French, Farid Meybodi, Kirsty Stuart, Tim Wang, Jeremy Hsu, Elisabeth Elder


  • Open Access

    Text message intervention delivered from Australian general practices to improve breast cancer survivors’ physical activity and cardiovascular risk factors: protocol for the EMPOWER-SMS-GP effectiveness implementation randomised controlled trial

    by Anna C Singleton, Stephanie R Partridge, Karice K Hyun, Christine Mitchell, Rebecca Raeside, Nashid Hafiz, Brooke Nickel, David Mizrahi, Allyson Ruth Todd, Jennifer McIntosh, et al.

    Introduction Australian breast cancer survivors are at increased risk of cardiovascular disease and mortality, partly due to behavioural risk factors, including unhealthy diet and physical inactivity. Guidelines recommend health promotion delivered by general practitioners (GPs), but resources (ie, time and funding) are limited. Text message interventions sent from general practice to survivors may offer a low-resource solution but have not been evaluated. This randomised controlled trial (RCT) aims to evaluate the effectiveness and implementation of a text message intervention called EMPOWER-SMS-GP in Australian general practices. Methods and analysis Multi-centre single-blind hybrid I RCT (n=678; 1:1 allocation) comparing EMPOWER-SMS-GP (n=339) to usual care (n=339) at 6 months (postintervention), 12, 18 and 24 months (maintenance) and parallel mixed-methods process evaluation using the Reach, Effectiveness, Adoption, Implementation and Maintenance framework. Inclusion: adults (≥18 years old) with early-stage breast cancer, completed active treatment ≤3 years ago, have a mobile phone and attended ≥1 GP appointment within 24 months. Primary outcome: between-group difference in mean physical activity (metabolic equivalent minutes/day) at 6 months, measured using an accelerometer. Secondary outcomes include self-reported physical activity, diet, quality of life, financial or psychological distress, fear of cancer recurrence, endocrine therapy adherence and body mass index. Statistical analyses (intention-to-treat) will include t-test (primary outcome) and linear and logistic mixed-effects regression models. Ethics and dissemination Approval received from the University of Sydney Human Research Ethics Committee (Number 2023/081). Trial results will be disseminated in peer-reviewed publications, presentations, lay summaries, videos and audio for scientific, government and public audiences. Trial registration number Australia and New Zealand Clinical Trial Registry (ACTRN12624000591550, 09/05/2024; U1111-1307-3454).


  • DIBH reduces right coronary artery and lung radiation dose in right breast cancer loco-regional radiotherapy

    by Ebony Gough, Simon Ashworth, Trevor Moodie, Wei Wang, Karen Byth, Rachael Beldham-Collins, Jacqueline Buck, Samer Ghattas, Lucinda Burke, Kirsty E. Stuart


  • Open Access

    The Development and Evaluation of an Educational Video for Breast Cancer Patients Requiring Adjuvant Radiation Therapy

    by Yvonne Moussa, Yobelli Jimenez, Wei Wang, Najmun Nahar, Verity Ahern, Kirsty Stuart

    Patient education and informed consent are required prior to adjuvant radiation therapy (RT) for early breast cancer (EBC), and include the role, rationale, potential toxicities and practicalities of the treatment process. Current education of patients about RT is verbal, in the form of a consultation by a radiation oncologist, often supplemented with print or online materials. This approach is limited by its doctor-dependency and non-standardised nature. Video education is being recognised increasingly as an opportunity to remediate this and appeal to patients’ preference for visual learning. The purpose of this study was to design and produce a video as an educational adjunct for EBC patients’ viewing prior to adjuvant RT, and to evaluate its acceptability through content analysis of three online focus group discussions, among ten participants with EBC requiring RT. After qualitative content analysis of the focus group transcripts, data were summarised into three main categories: (1) understanding of RT, (2) ease of engagement with the video and (3) anxiety and preparedness for RT. The 18-min video was positively received by all participants, and discussion feedback was used to inform improvements to the video. This focus group study demonstrated that the video was well understood, informative and acceptable to EBC patients in preparing them for RT. The effectiveness of the video in improving knowledge and alleviating distress in preparation for therapy will be further evaluated in an ethics-approved biphasic quasi-experimental study.


  • Reliability and Measurement Error of Breast Volume Calculation Using Three-Dimensional Surface Imaging

    by Nicola Fearn, Farid Meybodi, Sharon Kilbreath, Elizabeth Dylke, Catalina Llanos, Carmen Swanton, Kirsty Stuart

    Background: Breast lymphedema after breast cancer is challenging to quantify. Three-dimensional (3D) surface imaging is one available technique to measure breast volume, however, the measurement properties of available software programs have not been fully determined. The aim of this study was to determine equivalency of measurements with two software programs as well as reliability, standard error of measurement (SEM), and smallest detectable change (SDC). Methods and Results: Retrospective three-dimensional surface imaging (3D-SI) of 100 breasts taken before or after breast conserving surgery for breast cancer were retrieved for reliability analysis. Three assessors followed a standardized measurement technique using two software programs, Vectra ® 3D Analysis Module (VAM) and Breast Sculptor ® . Mean breast volume was 489.9 ± 206 cc using VAM and 480.1 ± 229.1 cc using Breast Sculptor. Lin's concordance showed poor agreement between programs (0.81–0.88). Measurements using VAM had excellent intra- and inter-rater reliability with SEM = 4.1% for one assessor and 8.7% for multiple assessors. Breast Sculptor also had excellent intra-rater and substantial inter-rater reliability but the SEM was much larger at 14.5% (intra-rater) and 19.1% (inter-rater). The SDC value was lowest for VAM and a single rater with 56 cc indicating a meaningful change beyond measurement error. Conclusion: Breast volume measurements captured with 3D-SI using VECTRA-XT are highly reliable, but the volumes, SEM, and SDC varied between the two software programs. Measurement error was lowest with VAM software. Although the usefulness of VECTRA-XT and VAM software to detect change in breast volume is promising, further solutions to reduce measurement error are required to improve clinical utility to measure breast lymphedema.


  • Diagnosis and management of phyllodes tumours for the surgeon: An algorithm

    by Adam Ofri, Kirsty E. Stuart, Belinda Chan, Cindy Mak, Sanjay Warrier, Vivek Bhadri, Tim Mander-Jones, Sandra O'TOole


  • Open Access

    Management of Early Breast Cancer at an Australian NSW Cancer Centre During the Early Phase of COVID-19 Pandemic

    by Elissa J. Zhang, Kirsty Stuart, Rina Hui, Rhiannon Mellor, Wei Wang, Verity Ahern, Farid Meybodi, James French, Elisabeth Elder, Meagan E. Brennan

    Background: This study aimed to prospectively record changes to treatment for early breast cancer patients during the first wave of the COVID-19 pandemic in Australia. The purpose was to assess the impact on breast cancer outcomes and to determine the need for any mitigative actions. Methods: The study was conducted in the breast cancer unit of a tertiary referral hospital. Consecutive patients with invasive cancer or ductal cancer in situ (DCIS) discussed in multidisciplinary team (MDT) meetings three times a week between March and June 2020 were included. Patients were newly diagnosed, post-operative or post-neoadjuvant chemotherapy. Standard treatment was defined by Westmead Breast Cancer Institute protocols and any variations related to the pandemic were recorded. Results:145 patients were included (median age 59 years). Pandemic related changes to management were noted in 13 of 145 (9·0%) patients discussed in the MDT meeting. Four patients experienced a delay to cancer treatments, four were not offered reconstructive/symmetrisation surgical procedures, three had altered radiotherapy protocols and two patients were not offered enrolment to a clinical trial. These impacts affected the groups presenting with new cancers (n=7/86, 8·1%), post-operative cases (n=4/25, 16·0%) and post-neoadjuvant chemotherapy cases presenting for surgical planning (n=2/34, 5·9%). Conclusion: Most patients (91·0%) received standard treatment during the first wave of the pandemic. Variations from institutional protocols are not expected to affect local control or survival in this patient cohort and no mitigative actions have been implemented. Quality of life may have been affected for four patients who had downgraded or delayed reconstructive procedures. Institutional strategies such as utilising telemedicine and COVID-free facilities were successfully implemented within the study period. Trial Registration: The study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12620000869976). Funding Statement: None. Declaration of Interests: RH has participated in advisory boards for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck, Merck Sharp and Dohme, Novartis, Oncosec, Pfizer, Roche and Seagen; and has received speaker honoraria from Merck Sharp and Dohme, Novartis and Roche. EE has participated in advisory board for Merck Sharp and Dohme. There are no conflicts of interests to declare for the other authors. Ethics Approval Statement: Approval was obtained from the Sydney West Human Research Ethics Committee (Project ID 2020/PID00900).

  • Open Access

    Verification using in vivo optically stimulated luminescent dosimetry of the predicted skin surface dose in patients receiving postmastectomy radiotherapy

    by Johnathon R. Wake, Feng Qin Chen, Simon Ashworth, Karen Byth, Wei Wang, Kirsty E. Stuart